A study to assess the safety, tolerability, and pharmacokinetics of FM101 after single and multiple ascending dose administration to healthy subjects.

开始日期2019-01-29

申办/合作机构

Oncology Central

100 项与 Oncology Central 相关的临床结果

登录后查看更多信息

0 项与 Oncology Central 相关的专利（医药）

登录后查看更多信息

225

项与 Oncology Central 相关的文献（医药）

2024-12-01·Biomolecular NMR Assignments

Backbone and methyl side-chain resonance assignments of the single chain Fab fragment of trastuzumab

Article

作者: Aramini, James M ; Aubin, Yves ; Gagné, Donald

AbstractTrastuzumab is a therapeutic monoclonal antibody developed to target human epidermal growth factor receptor 2 (HER2) present at higher levels in early cancers. Here we report the near complete resonance assignment of trastuzumab-scFab fragment backbone and the methyl groups of isoleucine, leucine and valine residues, as well as their stereo-assignments. The antibody fragment was produced using a single chain approach in Escherichia coli.

2024-12-01·Biomolecular NMR Assignments

Backbone and methyl side-chain resonance assignments of the Fab fragment of adalimumab

Article

作者: Aubin, Yves ; Sarker, Muzaddid

AbstractAdalimumab is a therapeutic monoclonal antibody developed to target human TNF an important mediator of immune-mediated inflammatory diseases such as rheumatoid arthritis, amongst others. The 48 kDa Fab fragment of adalimumab was produced in Escherichia coli using a single chain approach to allow complete isotopic incorporation of deuterium, carbon-13 and nitrogen-15 along with the protonated isoleucine-d, valine and leucine methyl groups. Here we report the near complete resonance assignment of the polypeptide backbone and the methyl groups of isoleucine, leucine and valine residues.

2024-11-01·Current Opinion in Oncology

Duodenal-type follicular lymphoma: comprehensive insights into disease characteristics and established treatment strategies

Review

作者: Fakih, Riad El ; Aljurf, Mahmoud ; Bakshi, Nasir ; Alnughmush, Ahmed ; Alyamany, Ruah ; Alhayli, Saud

Purpose of reviewThis review aims to detail the characteristics and outcomes of duodenal-type follicular lymphoma (DTFL), a rare lymphoma variant. It focuses on integrating recent reports in treatment modalities and highlights emerging insights into the unique biological features of the disease.Recent findingRecent studies confirm the indolent nature of DTFL, with extended follow-up periods showing favorable outcomes under watchful waiting strategies and a notable proportion of patients experiencing spontaneous remission. Additionally, advancements in understanding the disease's biology revealed that the tumor microenvironment is marked by specific genomic expressions indicative of chronic inflammation.SummaryThe observations of spontaneous resolution and the generally favorable progression of DTFL call for a conservative approach in initiating treatment. Clinical management should judiciously consider the disease's typically benign course against the potential risks of intervention, promoting customized treatment protocols tailored for cases with clinical necessity. Additionally, the discovery of an inflammatory tumor microenvironment and molecular evidence suggesting an antigen-driven process highlight critical areas for future research.

100 项与 Oncology Central 相关的药物交易

登录后查看更多信息

100 项与 Oncology Central 相关的转化医学

登录后查看更多信息